Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes.
We herein review published findings on the clinical characteristics of acromegalic patients harboring pituitary somatotrophinomas expressing adenylyl cyclase activating gsp mutations and present an update of our own data on a large series of 176 patients with and without these oncogenes. Gsp oncogenes are the result of point mutations in either codon 201 or 227 of the Gs-alpha subunit of the Gs-protein which controls adenylyl cyclase. They result ultimately in increased intracellular cAMP levels and thus in excessive growth hormone (GH) secretion. Our large series has allowed us to characterise patients with mutations in codon 201 and the far rarer group possessing codon 227 defects. Both groups were compared with patients without gsp oncogenes. In accordance with previous findings, there was no statistically significant difference in age of the patients belonging to each group, the overall average tumor diameter nor in pre-operative serum GH levels, although the latter showed a tendency to be lower in patients with gsp oncogenes. The distribution of different types of response during an oral glucose tolerance test (no change, paradoxical rise or greater than 50% decrease in serum GH levels) did not differ between the 3 groups. However, the incidence of microadenomas was higher in acromegalics expressing gsp oncogenes in patients possessing mutations in codon 227. Additionally, the incidence of invasiveness was much lower (10% v. 33%) in those tumors with mutations in codon 227. Finally, previous in-vitro data indicating that gsp oncogene-expressing tumors may respond more efficiently to the somatostatin analogue, octreotide, have been confirmed by subsequent in-vivo studies showing a better reduction in serum GH levels in patients with gsp oncogenes. These latter findings suggest that presence of gsp oncogenes may be a marker for good reponsiveness to octreotide. Assessment of gsp oncogene status of surgically removed pituitary somatotrophinomas may thus be helpful in designing optimal medical therapies in those acromegalics requiring further post-operative management of the disease.
Buchfelder
M
M
Department of Neurosurgery, University of Erlangen-Nürnberg, Germany. michael.buchfelder@neurochir.med.uni.erlangen.de
Fahlbusch
R
R
Merz
T
T
Symowski
H
H
Adams
E F
EF
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D000236:Adenoma / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D001483:Base Sequence; D003062:Codon / Q000235:genetics; D019205:GTP-Binding Protein alpha Subunits, Gs / Q000235:genetics*; D015870:Gene Expression; D005951:Glucose Tolerance Test; D006728:Hormones / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use; D009857:Oncogenes; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D017354:Point Mutation
D003062:Codon; D006728:Hormones; D019382:Human Growth Hormone; D019205:GTP-Binding Protein alpha Subunits, Gs; D015282:Octreotide